FDA Granted Breakthrough Status to ScolimiR-3D Blood Test

The diagnostic test is designed to assess the risk of progression in adolescent idiopathic scoliosis patients.

Updated on Sept. 29, 2026 in Life Sciences

Isometric editorial illustration of a clinical blood-collection vial, representing the new medical diagnostic testing technology. — The FDA has granted breakthrough status to the ScolimiR-3D blood test, the first diagnostic tool designed to predict disease progression in adolescent scoliosis patients. AI Illustration. Upload story photo >

Live Poll

Do you believe early predictive diagnostic blood tests lead to better long-term health outcomes for patients?

The FDA has awarded Breakthrough Device Designation to the ScolimiR-3D blood test, marking it as the first predictive diagnostic tool of its kind for scoliosis. The test helps physicians identify which patients are at risk of developing a severe spinal curve.

Why it matters

Clinicians currently lack objective diagnostic tools to determine which scoliosis patients face a high risk of disease progression. This test aims to fill that gap by providing a predictive assessment via a standard blood draw.

The test measures six circulating microRNAs to assess disease risk. Validation testing involved a sample size of 116 patients.

The players

FDA

The FDA is the federal agency responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs, biological products, and medical devices.

Scoliosis Research Society

The Scoliosis Research Society is a professional medical organization dedicated to the research and treatment of spinal deformities.

The details

ScolimiR-3D utilizes a standard blood draw to analyze a panel of six microRNAs to classify a patient's risk of developing a severe spinal curve. The foundational science behind the diagnostic method was published in Scientific Reports.

February 12, 2025: Underlying science published in Scientific Reports.
September 29, 2026: FDA Breakthrough Device Designation announced.
October 6-10, 2026: Scoliosis Research Society 2026 Annual Meeting in Sydney.

Arthritis
Sept. 28
FDA Cleared New SI-BONE Spinal Fusion System
Artificial Intelligence
Sept. 21
FDA Cleared New AI Tool for CT Scan Triage
Healthcare
Sept. 22
TriSalus Life Sciences Received FDA Clearance

The Big Picture

This diagnostic test represents a significant shift toward molecular-level assessment in orthopedic care, potentially replacing legacy diagnostic methods that rely solely on physical observation. The technology bridges the gap between genomic research and clinical spinal management.

This diagnostic tool could eventually transform how scoliosis is managed by enabling earlier, less invasive intervention for at-risk patients. Future clinical adoption may provide families with clearer roadmaps for long-term spinal health treatment.

The takeaway

The FDA designation highlights a broader trend of integrating blood-based biomarkers into orthopedic diagnostics to personalize patient care. Healthcare providers should monitor for upcoming clinical data to understand how this test integrates into standard spinal screening workflows.

What happens next

Additional research supporting the ScolimiR-3D technology is scheduled to be presented at the Scoliosis Research Society 2026 Annual Meeting, occurring October 6-10, 2026, in Sydney.